Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
8-10 January 2024

13rd Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel, San Francisco

CA

United States

7 January 2024

7th Sachs Annual Neuroscience Innovation Forum

Marine’s Memorial Club, San Francisco

CA

United States

3 January 2024

ORYZON to provide corporate progress updates at several events in January

4 December 2023

ORYZON awarded with a grant for ORY-4001 from the ALS Association in the U.S.

21 November 2023

ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million

7 November 2023

ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)

14-16 November 2023

Jefferies London Healthcare Conference 2023

Waldorf Hilton

London

United Kingdom

13 November 2023

LSX Investival Showcase 2023

Old Billingsgate

London

United Kingdom

6-15 November 2023

BIO-Europe 2023

Trade Fair Center Messe München

Munich

Germany

6 November 2023

ORYZON to provide corporate progress updates at several events in November

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Current page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel